Hosseini, 33 patient vitamin D prophylaxis RCT: 69% fewer cases [p=0.45] https://c19p.org/hosseini4
copied to clipboard
Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT): Ancillary Study of a Randomized Controlled Trial
et al., NCT04483635 (Preprint)
Early terminated prophylaxis RCT for healthcare workers in Canada, showing 0/18 cases with vitamin D prophylaxis vs. 1/15 for control. Results are published in [Hosseini]. 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks.
|
risk of case, 68.8% lower, RR 0.31, p = 0.45, treatment 0 of 18 (0.0%), control 1 of 15 (6.7%), NNT 15, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Hosseini et al., 5/20/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, North America, preprint, 1 author, dosage 100,000IU day 1, 10,000IU day 7, 10,000IU day 14, 10,000IU day 21, 10,000IU day 28, 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks, trial NCT04483635 (PROTECT).
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.